Press release content from Business Wire. The AP news staff was not involved in its creation.
Tezepelumab Is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients
February 26, 2021 GMT
WILMINGTON, Del. (BUSINESS WIRE) Feb 26, 2021
Positive full results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab demonstrated a statistically significant and clinically meaningful 1 reduction in the annualized asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients. 2 The results were presented at the American Academy of Asthma Allergy & Immunology Virtual Annual Meeting. 2
Tezepelumab, a potential first-in-class medicine, when added to standard of care (SoC) achieved a 56% reduction (p 0.001) in AAER over 52 weeks in the overall patient population, compared to placebo when added to SoC. 2 SoC was medium- or high-dose inhaled corticosteroids (ICS) plus at least one addition
Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen behind the current coronavirus disease 2019 (COVID-19) pandemic is a coronavirus of the betacoronavirus family. However, there are other human seasonal coronaviruses that cause endemic human infection, with mild common cold symptoms. The spectrum of SARS-CoV-2 infection also ranges from mild symptoms like a runny nose, nasal congestion or mild fever, to severe gastrointestinal or respiratory disease, sometimes terminating in multi-organ failure.
SARS-CoV-2 vs HCoV-OC43 infection
The complications of COVID-19 are observed in less than a tenth of patients, with risk factors for these including male sex, advanced age, ethnic background, lack of healthcare access, and pre-existing conditions. The majority of infections are asymptomatic.
Newark, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) As per the report published by Fior Markets, the global lupus therapeutics market is expected to grow from USD .